Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Braze Inc (BRZE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Braze Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Braze Inc trades at $28.27 (market cap $3.18B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.3× Braze Inc's market cap, and Braze Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BRZE | |
|---|---|---|
Market Cap | $29.60B | $3.18B |
Sector | Health | Technology |
52-Week High | $491.22 | $36.19 |
52-Week Low | $205.48 | $15.79 |
Enterprise Value | $27.56B | $2.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BRZE trades at $27.68, down 3.72% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is strong at 30% year-over-year, though the company remains unprofitable with a net margin of -15.51%. Recent news highlights insider selling and a 15% weekly rebound amid AI sector momentum.
The stock offers growth exposure with a consensus price target of $34.78, but risks include persistent losses, competitive pressures, and high valuation multiples. Analyst sentiment is overwhelmingly bullish, yet profitability challenges and insider sales warrant caution for investors seeking near-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
